Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
02 Feb 2024
02 Feb 2024
Historique:
received:
23
03
2023
accepted:
09
01
2024
medline:
6
2
2024
pubmed:
6
2
2024
entrez:
5
2
2024
Statut:
aheadofprint
Résumé
Treatment intensification has improved survival in patients with hepatoblastoma (HB); however, these treatments are associated with an increased risk of late effects, including second malignant neoplasms (SMNs). Data is limited regarding SMNs following HB treatment. Cases of SMNs following treatment for HB reported in the literature and from personal communication were analyzed to further assess this late effect. Thirty-eight patients were identified. The median age at diagnosis of HB was 16 months (range: 3 to 168 mo). All patients had received a platinum agent, and almost all had anthracycline exposure. The SMNs reported were hematopoietic malignancies (n=19), solid tumors (n=12), and post-transplant lymphoproliferative disorder (n=7). Of the 36 patients with outcome data, 19 survived. SMNs following HB treatment were primarily seen in patients with chemotherapy exposure, a history of liver transplantation, hereditary tumor predisposition syndromes, and/or a history of radiation treatment. Hematopoietic malignancies were the most common SMN reported in this cohort and were diagnosed earlier than other SMNs. Prospective collection of data through a companion late effects study or international registry could be used to further evaluate the rates and risks of SMNs as well as tumor predisposition syndromes in patients treated for HB.
Identifiants
pubmed: 38316145
doi: 10.1097/MPH.0000000000002824
pii: 00043426-990000000-00371
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26:19–28.
Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14:834–842.
Katzenstein H, Langham M, Malogolowkin M, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children’s Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019;20:719–727.
Brock P, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378:2376–2385.
Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA. 2017;317:814–824.
Reulen R, Frobisher C, Winter D, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011;305:2311–2319.
Olsen J, Möller T, Anderson H, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst. 2009;101:806–813.
Hjorth L, Haupt R, Skinner R, et al. Survivorship after childhood cancer: PanCare: a European Network to promote optimal long-term care. Eur J Cancer. 2015;51:1203–1211.
Armstrong G, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833–842.
Zong X, Pole JD, Grundy PE, et al. Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: a population-based study. Eur J Cancer. 2017;84:173–183.
Ishida Y, Maeda M, Adachi S, et al. Secondary cancer after a childhood cancer diagnosis: viewpoints considering primary cancer. Int J Clin Oncol. 2018;23:1178–1188.
Dembowska-Baginska B, Wieckowska J, Brozyna A, et al. Health status in long-term survivors of hepatoblastoma. Cancers. 2019;11:1777.
Hiyama E, Hishiki T, Watanabe K, et al. Outcome and late complications of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. J Clin Oncol. 2020;38:2488–2498.
Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008;44:257–268.
Kim SH, Shin KH, Seok SO, et al. Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency. Ann Surg Oncol. 2015;22:859–865.
Pole JD, Gu LY, Kirsh V, et al. Subsequent malignant neoplasms in a population-based cohort of pediatric cancer patients: a focus on the first 5 years. Cancer Epidemiol Biomarkers Prev. 2015;24:1585–1592.
Takahashi Y, Terui K, Chinen Y, et al. A pediatric case of secondary T-cell acute lymphoblastic leukemia with KMT2A-MAML2 developing after hepatoblastoma treatment. Pediatr Blood Cancer. 2020;67:e28033.
Koishi S, Kubota M, Taniguchi Y, et al. Myelodysplasia in a child with Beckwith-Wiedemann syndrome previously treated for hepatoblastoma with multi-agent chemotherapy. J Pediatr Hematol Oncol. 1996;18:419–420.
Hirakawa M, Nishie A, Asayama Y, et al. Efficacy of preoperative transcatheter arterial chemoembolization combined with systemic chemotherapy for treatment of unresectable hepatoblastoma in children. Jpn J Radiol. 2014;32:529–536.
Koga Y, Matsuzaki A, Suminoe A, et al. Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma. Pediatr Blood Cancer. 2008;50:943–944.
Barrena S, Hernandez F, Miguel M, et al. High-risk hepatoblastoma: results in a pediatric liver transplantation center. Eur J Pediatr Surg. 2011;21:18–20.
Özkan E, Özdemir B, Akcay E, et al. T-cell acute lymphoblastic leukemia after liver transplant. Exp Clin Transplant. 2014;12:139–141.
Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:2665–2675.
Haberle B, Maxwell R, Schweinitz DV, et al. High dose chemotherapy with autologous stem cell transplantation in hepatoblastoma does not improve outcome. results of the GPOH study HB99. Klin Padiatr. 2019;231:283–290.
Thway K, Judson I, Fisher C. Clear cell sarcoma-like tumor of the gastrointestinal tract, presenting as a second malignancy after childhood hepatoblastoma. Case Rep Med. 2014;2014:984369.
Weinblatt ME, Siegel SE, Siegel MM, et al. Preoperative chemotherapy for unresectable primary hepatic malignancies in children. Cancer. 1982;50:1061–1064.
Nguyen T, Makena M, Yavvari S, et al. Sarcoma as second cancer in a childhood cancer survivor: case report, large population analysis and literature review. Medicina. 2020;56:224.
Sanchez G, Eguiguren J, Villanueva E, et al. SIOPEL protocol for hepatoblastoma in children. Experience of a Latin-American Paediatric Oncology Center. Pediatr Blood Cancer. 2016:S174.
O’Neill AF, Adil EA, Irace AL, et al. Post-transplant lymphoproliferative disorder of the pediatric airway: presentation and management. Int J Pediatr Otorhinolaryngol. 2016;86:218–223.
Ng K, Rana A, Masand P, et al. Fatal central nervous system post-transplant lymphoproliferative disease in a patient who underwent liver transplantation for hepatoblastoma. J Pediatr Gastroenterol Nutr. 2018;66:e21–e23.
Koneru B, Flye MW, Busuttil RW, et al. Liver transplantation for hepatoblastoma. The American experience. Ann Surg. 1991;213:118–121.
Samuk I, Tekin A, Tryphonopoulos P, et al. Abdominal transplantation for unresectable tumors in children: the zooming out principle. Pediatr Surg Int. 2016;32:337–346.
Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004;42:74–83.
Turcotte L, Liu Q, Yasui Y, et al. Chemotherapy and risk of subsequent malignant neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2019;37:3310–3319.
Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol. 1994;22:1–10.
Teepen JC, Kok JL, Kremer LC, et al. Long-term risk of skin cancer among childhood cancer survivors: a DCOG-LATER cohort study. J Natl Cancer Inst. 2019;111:845–853.
Le Deley M, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique. J Clin Oncol. 2003;21:1074–1081.
Travis LB, Wahnefried WD, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10:289–301.
Hawkins MM, Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ. 1992;304:951–958.
Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682–1687.
Henderson TO, Moskowitz CS, Chou JF, et al. Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2016;34:910–918.
Ramos-Gonzalez G, Crum R, Allain A, et al. Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center. Pediatr Transplant. 2022;26:e14268.
Ruth ND, Kelly D, Sharif K, et al. Rejection is less common in children undergoing liver transplantation for hepatoblastoma. Pediatr Transplant. 2014;18:52–57.
Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618–629.
Perentesis JP. Genetic predisposition and treatment-related leukemia. Med Pediatr Oncol. 2001;36:541–548.
Inoue K, Asao T, Shimada T. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica. 2000;30:285–295.